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immunotherapy. The challenge is to safely target oncolytic
viruses to tumors. Previously, we have generated influenza A
viruses (IAVs) containing deletions in the viral interferon antag-
onist. Those deletions have attenuated the virus in normal tissue
but allowed replication in tumor cells. IAV entry is mediated by
hemagglutinin (HA), which needs to be activated by a serine
protease, for example, through trypsin. To further target the
IAV to tumors, we have changed the trypsin cleavage site to
an elastase cleavage site.We chose this cleavage site because elas-
tase is expressed in the tumormicroenvironment.Moreover, the
exchange of the cleavage site previously has been shown to atten-
uate viral growth in lungs. Newly generated elastase-activated
influenza viruses (AE viruses) grew to similar titers in tumor
cells as the trypsin-activated counterparts (AT viruses). Intratu-
moral injection of AE viruses into syngeneic B16f1 melanoma-
derived tumors in mice reduced tumor growth similar to AT
viruses and had a better therapeutic effect in heterologous
human PANC-1-derived tumors. Therefore, the introduction
of the attenuation marker “elastase cleavage site” in viral HA
allows for safe, effective oncolytic virus therapy.
INTRODUCTION
The main strategy of oncolytic viral therapy is based on the fact that
naturally occurring or engineered viruses are able to conditionally
infect tumor cells and replicate in them, thereby inducing cell lysis.1
The viral tropism to malignant cells is usually dependent on molecu-
lar alterations in cancer cells acquired during carcinogenesis, which
leads to the loss of viral defense mechanisms, thus enabling viral
amplification.2 These alterations of cancer cells involve defects in
the interferon (IFN), p53, and pRb pathways along with an activation
of the Ras/Raf1/MEK/ERK pathway3–5 or alterations in vessel walls. A
number of phase II and phase III clinical trials using vaccinia, herpes
virus, or adenoviruses have indicated the beneficial results of virother-
apy, calling for the development of less explored virus families to
generate clinically applicable prototypes of oncolytic viruses.6
We have generated an oncolytic influenza A virus (IAV) using the
above-mentioned principles of molecular targeting of the virus toThis is an open access article under the CC BY-NCcancer cells. Specifically, we have shown that an attenuated vaccine
prototype virus which lacks full-length NS1 protein, the viral antago-
nist of PKR,7 efficiently replicates in vitro in IFN-defective8 and RAS
mutant cancer cells.9 Correspondingly, this prototype was effective as
an oncolytic agent in different models in vivo.8 Continuous passaging
of the oncolytic IAV resulted in adaptive mutations throughout
the viral genome, which led to enhanced stability and growth for
both tumor and producer cell lines without affecting pathogenicity.10
We hypothesized that the modification of the cleavage site of the
hemagglutinin (HA), the viral entry protein, might further promote
a conditionally replicative growth in tumors. The cleavage of HA
by host proteases is an essential step in the life cycle of IAV, allowing
multi-cycle replication and viral spread within infected tissue. All
IAVs containing a monobasic cleavage site (a single Arg or Lys resi-
dues) require the presence of trypsin or trypsin-like serine proteases
for activation.11,12 Such proteases are typically found in the upper res-
piratory tract as well as in the gastrointestinal tract. For this reason,
IAV infection is primarily limited to these sites. It was demonstrated
that an IAV containing an elastase cleavage site in its HA is
attenuated in mice and pigs.13–17 Thus, an alteration of HA protease
susceptibility can attenuate viral spread.18 Importantly, malignant tis-
sue is known to express proteases which promote tumor invasion.
These proteases are either expressed by invading immune cells,
such as neutrophils and macrophages, or by tumor cells themselves.
They form a protease-rich environment around those malignant cells
facilitating activation of oncolytic viruses.19
In this study, we investigated whether an attenuated IAVwith an elas-
tase-sensitive HA cleavage site is able to replicate in tumor cells and
exerts an oncolytic effect in vivo. For this, we modified the HA of a
previously generated GFP-expressing tumor adapted influenza A
NS116-GFP/A virus.
10 This alteration did not change viral growthMolecular Therapy: Oncolytics Vol. 7 December 2017 ª 2017 37
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Schematic Representation of Modifications in the HA Cleavage
Site
The cleavage site is indicated by bold letters. The amino acids changed during
adaptation to elastase are shown in red.
Figure 2. Growth Kinetic of Modified NS116-GFP/AE Virus
A 24-hr-old monolayer of Vero cells was infected with NS116-GFP/AE virus in the
presence of either pancreatic elastase (p-elastase) or neutrophil elastase (n-elas-
tase). A viral titer was determined by TCID50 in Vero cells at the indicated time
points + SEM (n = 6).
Molecular Therapy: Oncolyticscharacteristics in vitro when the suitable protease was added and
multi-cycle viral replication remained when infected cells were co-
cultivated with isolated neutrophils. Intratumoral application of the
generated virus had an efficient therapeutic effect when different tu-
mor models were used.
RESULTS
To obtain an elastase-dependent viral vector, we took advantage of
the high mutability of influenza viruses and their ability to adapt. A
trypsin-dependent influenza DNS1-H1N1 virus20 expressing an HA
from influenza A/New Caledonia/20/99 virus was serially passaged
on Vero cells in the presence of porcine pancreatic elastase. After 6
passages, we obtained a virus DNS1-H1N1-E, which could grow to
a titer of 7 log 50% tissue culture infective dose (TCID50/ml) on
Vero cells in the presence of porcine pancreatic elastase. Interestingly,
the resulting virus was also sensitive to human neutrophil elastase
activation (Figure S1). Sequence analysis of the HA gene revealed
three nucleotide changes at positions 1056, 1060, and 1061 from T,
G, A to C, T, G, respectively. Those changes corresponded to two
amino acid substitutions at the cleavage site of the HA molecule:
serine and arginine at positions 342 and 343 were replaced by proline
and isoleucine, respectively (Figure 1). These mutations were
then introduced into the genome of the previously described NS116-
GFP/A10 virus by side-directed mutagenesis of the HA coding
plasmid using standard reverse genetics methods developed for influ-
enza virus.21,22 Obtained mutant was named NS116-GFP/AE and was
sensitive to activation by porcine pancreatic elastase and human
neutrophil elastase (Figure 2). The parental virus which is activated
by trypsin was named “NS116-GFP/AT.” We used this virus, as it
has previously been shown to serve as a stable viral vector. Moreover,
NS116-GFP/AT did not show any toxicity when systemically
administrated by the intravenous route at a titer of 108 TCID50 in
mice (Figure S2). No infectious virus was isolated from brain, lungs,
liver, gut, muscle, or kidney, indicating the lack of virus dissemination
after systemic administration. Since a significant attenuation of elas-
tase-dependent influenza virus in comparison with trypsin-depen-
dent virus in mice model has been already shown,15,17 we did not
perform further biodistribution assays.
Next, we compared the protease-specificity of viruses NS116-GFP/AE
and NS116-GFP/AT for trypsin, neutrophilic elastase or supernatant
of human neutrophils. For later purposes, we determined the viral
yield in a co-cultivation system of infected Vero cells with human
neutrophils. The NS116-GFP/elastase-activated influenza virus
(AE virus) grew to the same titers in the presence of neutrophils38 Molecular Therapy: Oncolytics Vol. 7 December 2017and in the presence of neutrophilic elastase, which were 7.06 log
TCID50/ml and 6.8 log TCID50/ml, respectively (Figure 3A). This
virus completely lost its reproductive activity in the presence of
trypsin. In contrast, the NS116-GFP/AT virus grew to the titer of
7.6 log TCID50/ml in the presence of trypsin, but not in the presence
of neutrophilic elastase or supernatants of neutrophils, indicating
the specificity of the cleavage site. These titers were in correlation
with the GFP expression in infected cells (Figure 3B). Our findings
support the hypothesis that tumor-infiltrating immune cells, such
as neutrophils, would produce elastase that is sufficient for HA
cleavage of the NS116-GFP/AE virus replicating in tumor cells during
oncolytic therapy.
To further address the growth properties of the elastase activated
virus, we compared multi-cycle growth of NS116-GFP/AE and
NS116-GFP/AT in Vero and B16f1 cells in the presence of neutro-
philic elastase or trypsin, respectively. Change of the cleavage site in
HA protein had no influence on the growth characteristic between
the two viruses (Figure 4). Also, the modification of the HA-cleavage
site did not lead to the growth disadvantages of NS116-GFP/AE virus
in human tumor cell lines, such as PANC-1 or A375 (Figure 4).
Trypsin-sensitive NS116-GFP/AT virus showed significantly higher
titer in comparison with elastase-sensitive NS116-GFP/AE virus on
the CaCo2 cell line. This might be explained by the endogenous pro-
duction of trypsin-like serine proteases in this cell line allowing HA
cleavage17 (Figure 4). None of the tested cell lines were able to support
the replication of NS116-GFP/AE virus without a source of exogenous
elastase (Figure S3). As expected the NS116-GFP/AT virus could repli-
cate only in CaCo2 cells without an addition of trypsin (Figure S3).
To test the oncolytic potential of NS116-GFP/AT and NS116-GFP/AE,
we intratumorally injected these viruses into a syngeneic murine
B16f1 model (Figure 5A). Administration of both, NS116-GFP/AT
or NS116-GFP/AE viruses significantly inhibited tumor outgrowth,
when compared to the control group (p < 0.05). There was no sub-
stantial difference between the two viruses. DNS1-H1N1 virus, a
Figure 3. Growth Properties of NS116-GFP/AE and
NS116-GFP/AT Virus in Vero Cells in Co-culture
System with Human Neutrophils or Supernatant
Supplemented with Neutrophil Elastase or Trypsin
(A) Vero cells were infected at an MOI of 0.01 under
indicated condition and viral titer was determined by
TCID50 24 hr post-infection. Data represent means +
SEM (n = 3). (B) Virus induced GFP expression, which
indicates viral growth. The pictures of infected Vero cells
were taken 48 hr post-infection using an AxioCam ICc3
Rev.2-3 camera, with a magnification of 200. Experi-
ments were carried out three times with neutrophils of
another proband, and the corresponding results are
provided. Scale bar, 100 mm.
www.moleculartherapy.orgcorresponding replication-deficient deltaNS1 virus lacking the com-
plete NS1 open reading frame, had no therapeutic effect in this model
(Figure S4). This complete NS1 deletion virus did not grow in B16f1
cells, indicating the critical role of virus replication for oncolytic
activity.
The pancreatic cell line PANC-1 was chosen to study the oncolytic
effect of the NS116-GFP/AE virus in a human tumor xenograft
model (Figure 5B). It had been previously shown that influenza vi-
rus has an oncolytic activity in pancreatic cell lines.23 Interestingly,
despite both viruses growing to comparable titers in PANC-1 cells
in vitro, the NS116-GFP/AE virus had a significantly better thera-
peutic effect in this model compared to the NS116-GFP/AT virus
(p < 0.05). We next determined the presence of influenza virus
in tumor tissue by immunohistochemistry (Figure 6). This analysis
indicated that both viruses replicated 7 days post-virus injections
in the malignant cells as shown by the overlapping staining pattern
of HA-specific and tumor-cell-specific signals. We did not observe
a positive staining signal for neutrophils. This suggests that virus-
activating elastase might have been produced by other cellular
sources.Molecular TDISCUSSION
The use of potentially pathogenic viruses for
oncolytic purposes calls for the development
of multiple attenuation markers within the vi-
rus, which do not inhibit efficient growth in ma-
lignant cells. In IAV, we have previously defined
such a marker when deleting a nonstructural
protein NS1 coded by segment 8. This study
examined another attenuation characteristic
for conditional growth in tumors. An altered
cleavage site of the hemagglutinin coded by
segment 4 achieved the attenuation. Similar to
the marker “NS1 deletion,” the marker “elastase
cleavage site” attenuates the virus in the upper
respiratory tissue, as has been previously
shown.16,24 Using two different murine models,
we demonstrated that the introduction of the
elastase cleavage site into the oncolytic influ-enza virus does not diminish the therapeutic properties of this onco-
lytic prototype in vivo. It should be noted that replication defective
influenza viruses have little effect in tumormodels, such as B16f1mel-
anoma (Figure S4). Thus, we conclude that the attenuation marker
“elastase cleavage site” leads to a conditional replication of the virus
in tumor tissue.
Pursuant to our in vitro data that neutrophilic elastase activated the
elastase-dependent oncolytic virus, we initially hypothesized that tu-
mor-infiltrating neutrophils could be the source for elastase in tumor
tissue. However, we did not detect neutrophils in the PANC-1 tumor
tissue where we observed a beneficial therapeutic effect of the elastase
activated virus. Alternative sources of elastase could be macro-
phages25,26 or tumor cells themselves. It was suggested that tumor
cells have a “protease cloud” surrounding their surface. This “protease
cloud” was shown to activate reovirus.19 However, as tumor cells in
culture do not activate the NS116-GFP/AE virus in the absence of
exogenous protease, it appears to be clear that the source of elastase
within such a “protease cloud” is provided or stimulated by cells of
the tumor microenvironment. Thus, activation of oncolytic viruses
by proteases appears to be a more general and valuable approach toherapy: Oncolytics Vol. 7 December 2017 39
Figure 4. Growth of NS116-GFP/AT and NS116-GFP/AE Viruses in Different Cell Lines
Vero, B16f1, PANC-1, A375, or CaCo2 1  105 cells were infected with either NS116-GFP/AT or NS116-GFP/AE viruses at an MOI of 0.01 and cultivated in the presence
trypsin or neutrophil elastase, respectively. Supernatant was collected 12, 24, 48, and 72 hr post-infection. Data represent means + SEM (n = 3).
Molecular Therapy: Oncolyticsensure virus targeting to tumors. We have now adapted this approach
for influenza virus.
Our data also support previous findings23 that pancreatic cancer
might be an attractive target for influenza virus oncolytic therapy.
This virolysis of pancreatic cells may be supported by (1) the inherent
susceptibility of pancreatic tissue to influenza virus23 and (2) by the
fact that PANC-1 as well as 90% of pancreatic cancers have a KRAS
gene mutation,27 leading to a suppression of the antiviral PKR
pathway. Pancreatic cancer tissue specifically might be a target for
elastase-dependent influenza virus given that the pancreatic cancer
microenvironment often expresses proteases including elastase.28
An attenuation marker in segment 4 is of specific interest for the safe
clinical application of the IAVs. The segmented nature of the virus
could allow the spread of the HA used by oncolytic viruses within
the population over an antigenic shift. A modification of the cleavage
site within the HAmolecule would prevent such a spread. In the same
line, the attenuation marker in the HA might better allow the use of
HA subtypes which are currently not circulating. This may be of spe-
cific interest for the repetitive use of the virus, as the exchange of the
HA subtype will prevent inhibition of the oncolytic virus by preexist-
ing immunity. Thus, introduction of the modified HA cleavage site
should allow a safe use of H5 and/or H7 subtype and might further
support application of selected H1 subtypes in cases of concern.40 Molecular Therapy: Oncolytics Vol. 7 December 2017Modulation of virus entry proteins to target viruses to cancer has pre-
viously been conducted with virus families other than orthomyxovi-
ruses.29–31 In this study, we applied this principle to IAV. A disadvan-
tage of this approach could be that virus-entry-protein-modified
viruses may impair viral growth, making production difficult and
cumbersome. However, we demonstrated that the elastase-dependent
virus grew as efficiently as the trypsin-activated virus in Vero cells,
which is the cell line licensed for use for virus production. This indi-
cates that the production of such viruses appears less of a problem.
In conclusion, we defined an attenuation maker, which allows condi-
tional replication of the influenza virus in malignant tissue. We believe
that this marker might be substantial to allow the use of rare HA influ-
enza subtypes for oncolytic purposes, as it increases the safety of the
therapeutic virus. Given that pancreatic tissue expresses pancreatic
elastase, oncolytic influenza viruses expressing an elastase cleavage
site might be of specific interest for pancreatic cancer.
MATERIALS AND METHODS
Cell Lines
All cell lines were purchased from the ATCC (ATCC, Manasses, VA,
USA). Human adenocarcinoma cell line PANC-1, human melanoma
cells A375, and mouse melanoma cells B16f1 were cultured in
DMEM/nutrient mixture F12 (GIBCO, Life Technologies, Grand Is-
land, NY, USA) supplemented with 10% fetal calf serum (FCS)
Figure 5. Effect of NS116-GFP/AT and NS116-GFP/AE Treatment on the Survival of B16f1 Melanoma- and PANC-1-Bearing Mice
(AandB)Seven6-week-oldC57/BL6orathymicnudemiceweresubcutaneously injectedwithB16f1 (A)orPANC-1 (B)cells.5daysafter implantationofmelanomacellsand10days
after implantationofpancreaticadenocarcinomacells, the treatmentwitheitherNS116-GFP/ATandNS116-GFP/AEviruswasstartedwith the intratumoral injectionof1107TCID50/
mouse. Treatmentwas repeatedondays 7,9, 11, and13 forC57/BL6mice and ondays12, 14, 16, and18 forPANC-1-bearingmice. The dose of theoncolytic viruswas increased
up to 1 108 TCID50 /mouse for the last two injections. Mice were sacrificed when tumor volumes reached 2000 mm3. ns, not significant. *p < 0.05, **p < 0.01.
www.moleculartherapy.org(GIBCO). Adenocarcinoma cell line CaCo2 wasmaintained in Eagle’s
Minimum Essential Medium (EMEM) (GIBCO) supplemented with
10% FCS. Monkey kidney epithelial (Vero) cells were cultured in
serum-free OptiPRO medium (GIBCO).
Viruses
TheDNS1-H1N1A/NewCaledonia virus20 contains HA andNA from
A/New Caledonia/20/99 (H1N1), PB1 of A/Texas/1/77 (H3N2), and
PA, PB2, NP, M, and NS are of PR8 origin A/Puerto Rico/8/34 and
were adapted by serial passages to grow on Vero cells in presence of
5 mg/ml porcine pancreatic elastase (Sigma-Aldrich, St. Louis,
MO, USA). Trypsin-dependent NS116-GFP/AT or elastase-dependent
NS1116-GFP/AE viruses were propagated at 37C in Vero cells
infected with MOI of 0.01 in the presence of either 1 mg L-1-Tosyla-
mide-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin
(Sigma Aldrich) ml1 or 10 mg human neutrophil elastase (Serva Elec-
trophoresis, Heidelberg,Germany)ml1. Virus titer was determined by
a TCID50 assay.
Plasmids
Viral RNA of DNS1-H1N1 virus was isolated from 280 ml of superna-
tant of infected cells using a QIAamp Viral RNA Mini Kit (QIAGEN,
Hilden, Germany), and cDNA was generated by using a Uni12 primer
(50-AGCAAAAGCAGG-30)21 and Superscript II RT (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s protocol.
The cDNA of the HA segment was amplified by PCR using
segment-specific primers,21 and nucleotide-sequencing analysis was
performed by GeneArt (Invitrogen). The revealed nucleotide changes
within the sequence of the HA cleavage site T1056C, G1060T, and
A1061G were introduced in pHW200022 vector coding HA of
NS116-GFP/A virus
10 by site-directed mutagenesis using the primers
50-CAT TCCGTCCATTCAACC CGC AGGTCTATT TGGAGC-30,
50- CAT TCC GTC CAT TCA ATC CGC AGG TCT ATT TGG
AGC-30, 50- GCT CCA AAT AGA CCT GCG GGT TGA ATGGAC GGA ATG-30, and 50- GCT CCA AAT AGA CCT GCG GAT
TGA ATG GAC GGA ATG-30.
Generation of the Viruses
The eight plasmid reverse genetic system22 was used to generate
NS116-GFP/AE virus, as previously described.
10 Briefly, 4 mg
of pHW2000 plasmids encoding single-gene segments of NS116-
GFP/AE were transfected into 1  106 of Vero cells using the Nucle-
ofector technique (Lonza, Basel, Switzerland). After transfection, cells
were incubated in OptiPRO medium containing 10 mg/ml neutrophil
elastase. When the cytopathic effect (CPE) reached 50%, supernatant
was collected and two consecutive passages were performed on Vero
cells before the virus stock was produced. The virus titer was deter-
mined by the TCID50 assay.
Determination of Viral Replication Kinetic
0.1  106 of A375, B16f1, Caco2, PANC-1, or Vero cells were seeded
in 12-well plates, and subconfluent monolayers of the cells were in-
fected the next day with the relevant virus at an MOI of 0.01. Cells
were incubated in the presence of TPCK-treated trypsin, neutrophil
elastase, or without any of proteases. The supernatant was collected
at the indicated time points, and the TCID50 assay was exploited
for the determination of virus titers.
Isolation of Human Polymorphonuclear Leukocytes
The trial was approved by the Ethics Committee of the Medical
University of Vienna (#455/2010). Human polymorphonuclear
leukocytes (PML) were isolated from peripheral blood of healthy
donors, as previously described.32 Briefly, fresh venous blood was
loaded on Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala,
Sweden) and centrifuged at 350  g for 35 min. PMLs were
collected and separated from the red blood cells by 6% dextran
500 (Sigma Aldrich) sedimentation, followed by hypotonic lysis
of the remaining erythrocytes.Molecular Therapy: Oncolytics Vol. 7 December 2017 41
Figure 6. Detection of Viral Proteins and Neutrophil
Infiltration in Tumor Tissue
2, 4, and 7 days after the first injection of either NS116-
GFP/AT or NS116-GFP/AE virus, PANC-1 tumors were
extracted and fixed in 3.7% formaldehyde. Immunohis-
tochemical staining of de-paraffinized sections was per-
formed using anti-hemagglutinin antibody (blue), anti-
neutrophil antibody (green), anti-cytokeratin-7 antibody
(as a marker of PANC-1 cells) (red), and DNA dye DRAQ5
(yellow). Scale bar, 20 mm.
Molecular Therapy: OncolyticsCo-cultivation of PMLs and Infected Vero Cells
0.5 106 Vero cells seeded in 12-well plates were infected with either
NS116-GFP/AT or NS116-GFP/AE virus at an MOI of 0.01 for 45 min
at room temperature. Subsequent inoculum was removed, and cells
were washed with PBS. Based on an estimated cellular amount of
neutrophil elastase equal to 3 pg/cell,33,34 5  106 of isolated PML
was resuspended in 1.5 mL of OptiPROmedium and placed in Trans-
well insert chambers (Costar, New York, NY, USA), preventing direct
contact between infected Vero and non-infected PMLs. As a control,
1.5 mL of OptiPRO medium containing either 1 mg/ml TPCK-
trypsin or 10 mg/ml human neutrophil elastase was used. 24, 48, 72,
and 96 hr post-infection supernatants were collected, and the virus ti-
ters were determined by TCID50 assay. The pictures of infected42 Molecular Therapy: Oncolytics Vol. 7 December 2017monolayers were taken by AxioCam ICc3
Rev.2-3 camera for a Zeiss Axiovert 40 CFL mi-
croscope (Zeiss, Jena, Germany).
TCID50 Assay
For the TCID50 assay, Vero cells were seeded in
96-well plates at a concentration of 3 106 cells/
plate. The medium was removed the next day,
and the cells were incubated for 45 min with
50 ml of 10-fold virus dilution in an OptiPRO
medium. After incubation, 50 ml of OptiPRO
medium containing 1 mg/ml trypsin was added
to each well. The virus titer was calculated 48 hr
later by the Reed and Muench method and pre-
sented as a log10 TCID50 per ml.
In Vivo Treatment of Established Tumor
All animal experiments were performed accord-
ing to the latest guidelines of the ‘‘Federation
of European Laboratory Animal Science
Associations (FELASA)” and approved by the
local committee of the Medical University of
Vienna (BMWF-66-009/0204-II/3b/2011). 6-
to 8-week-old female mice were purchased
from Charles River Laboratories (Sulzfeld, Ger-
many). For the syngeneic tumor model, 5 105
B16f1 cells resuspended in 100 ml of PBS were
subcutaneously injected into the right groin of
C57BL/6 mice (n = 7). For the heterologous tu-mor model, 3 106 PANC-1 cells resuspended in 100 ml of PBS were
injected in the right flank of athymic nude mice (n = 8). Administra-
tion of the therapeutic viral injections began 5 and 10 days after the
tumors were visible and were 2–3 mm in diameter for B16f1 and
PANC-1 cells, respectively. Tumor size was measured using digital
calipers each second day, and tumor volume (V) was calculated using
the formula V = ðpba2=6Þ, where a is the smallest diameter and b is
the perpendicular diameter.
Immunohistofluorescence
5-mm tissue sections of paraffin-embedded PANC-1 tumors were re-
hydrated and then stained for 1 hr with rabbit anti-cytokeratine-8
antibody diluted 1:100 (Abcam, Cambridge, UK) to detect PANC-1
www.moleculartherapy.orgcells; sheep anti-HA-antibody was diluted 1:200 to detect influenza-
infected cells; and rat anti-mouse Ly-6B.2 was diluted 1:50 to detect
neutrophils (AbD Seotech, Oxford, UK). Tissue sections were washed
twice with PBS and incubated with secondary antibody: anti-rat Alexa
Fluor 488, anti-rabbit Alexa Fluor 555, or anti-sheep Alexa Fluor 633
(Thermo Scientific, Waltham, MA, USA) for 1 hr, followed by
washing with PBS and incubation with 5 mM DRAQ5 (Thermo Sci-
entific) to stain nuclei. The images were acquired using Carl Zeiss
LSM 700 confocal microscope.
Statistical Analysis
Statistical analysis was performed by two-tailed Student t test, and
Kaplan-Meyer survival curves were compared using the log-rank
(Mantel-Cox) test (Prism 5, Graph Pad Software).
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